These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 39137049

  • 21. Discontinuation of renin-angiotensin system inhibitors brings no benefits in severe chronic kidney disease.
    Volpe M, Patrono C.
    Eur Heart J; 2024 Jul 09; 45(26):2279-2280. PubMed ID: 38703142
    [No Abstract] [Full Text] [Related]

  • 22. Transforming the Care of Patients with Diabetic Kidney Disease.
    Brosius FC, Cherney D, Gee PO, Harris RC, Kliger AS, Tuttle KR, Quaggin SE, DKD-Collaborative ASN Taskforce.
    Clin J Am Soc Nephrol; 2021 Oct 09; 16(10):1590-1600. PubMed ID: 34103350
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. The evolution of angiotensin blockade in the management of cardiovascular disease.
    Nantel P, René de Cotret P.
    Can J Cardiol; 2010 Dec 09; 26 Suppl E():7E-13E. PubMed ID: 21620285
    [Abstract] [Full Text] [Related]

  • 25. Angiotensin receptor blockers are associated with lower mortality than ACE inhibitors in predialytic stage 5 chronic kidney disease: A nationwide study of therapy with renin-angiotensin system blockade.
    Lin CC, Wu YT, Yang WC, Tsai MJ, Liu JS, Yang CY, Li SY, Ou SM, Tarng DC, Hsu CC.
    PLoS One; 2017 Dec 09; 12(12):e0189126. PubMed ID: 29216260
    [Abstract] [Full Text] [Related]

  • 26. Effects of cilostazol and renin-angiotensin system (RAS) blockers on the renal disease progression of Korean patients: a retrospective cohort study.
    Noh Y, Lee J, Shin S, Park I, Bae SK, Oh E, Lee S.
    Int J Clin Pharm; 2018 Feb 09; 40(1):160-168. PubMed ID: 29282632
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Juxtaglomerular apparatus hyperplasia under dual angiotensin blockade. A footprint of adequate RAS inhibition or a concern for renal fibrosis?
    Fernandez-Fernandez B, Ortiz A, Gomez-Guerrero C, Barat A, Martín-Cleary C, Egido J.
    BMC Nephrol; 2012 Apr 25; 13():21. PubMed ID: 22533828
    [Abstract] [Full Text] [Related]

  • 29. The Use of Renin-Angiotensin System Inhibitors in Patients With Chronic Kidney Disease.
    Leon SJ, Tangri N.
    Can J Cardiol; 2019 Sep 25; 35(9):1220-1227. PubMed ID: 31472818
    [Abstract] [Full Text] [Related]

  • 30. Renoprotective effect of renin-angiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia.
    Hsu TW, Liu JS, Hung SC, Kuo KL, Chang YK, Chen YC, Hsu CC, Tarng DC.
    JAMA Intern Med; 2014 Mar 25; 174(3):347-54. PubMed ID: 24343093
    [Abstract] [Full Text] [Related]

  • 31. Renin-angiotensin system blockers and residual kidney function loss in patients initiating peritoneal dialysis: an observational cohort study.
    Shen JI, Saxena AB, Vangala S, Dhaliwal SK, Winkelmayer WC.
    BMC Nephrol; 2017 Jun 17; 18(1):196. PubMed ID: 28623899
    [Abstract] [Full Text] [Related]

  • 32. Effects of Renin-Angiotensin-Aldosterone System Blockade in Patients with End-Stage Renal Disease.
    Slomka T, Lennon ES, Akbar H, Gosmanova EO, Bhattacharya SK, Oliphant CS, Khouzam RN.
    Am J Med Sci; 2016 Mar 17; 351(3):309-16. PubMed ID: 26992264
    [Abstract] [Full Text] [Related]

  • 33. Mitigation of radiation injuries via suppression of the renin-angiotensin system: emphasis on radiation nephropathy.
    Cohen EP, Fish BL, Moulder JE.
    Curr Drug Targets; 2010 Nov 17; 11(11):1423-9. PubMed ID: 20583975
    [Abstract] [Full Text] [Related]

  • 34. Clinical and hemodynamic effects of renin-angiotensin system blockade in cardiac transplant recipients.
    Karabsheh S, Verma DR, Jain M, Stoddard G, Brunisholz K, Stehlik J, Kfoury A, Gilbert E, Bader F.
    Am J Cardiol; 2011 Dec 15; 108(12):1836-9. PubMed ID: 22133132
    [Abstract] [Full Text] [Related]

  • 35. Effect of Angiotensin-converting enzyme inhibitors and Angiotensin receptor antagonists in atherosclerosis prevention.
    Patarroyo Aponte MM, Francis GS.
    Curr Cardiol Rep; 2012 Aug 15; 14(4):433-42. PubMed ID: 22562592
    [Abstract] [Full Text] [Related]

  • 36. Renin-angiotensin-aldosterone system inhibitors in heart failure.
    Shearer F, Lang CC, Struthers AD.
    Clin Pharmacol Ther; 2013 Oct 15; 94(4):459-67. PubMed ID: 23852393
    [Abstract] [Full Text] [Related]

  • 37. Present and future in the treatment of diabetic kidney disease.
    Quiroga B, Arroyo D, de Arriba G.
    J Diabetes Res; 2015 Oct 15; 2015():801348. PubMed ID: 25945357
    [Abstract] [Full Text] [Related]

  • 38. The Impact of Renin-Angiotensin System Blockade on Renal Outcomes and Mortality in Pre-Dialysis Patients with Advanced Chronic Kidney Disease.
    Oh YJ, Kim SM, Shin BC, Kim HL, Chung JH, Kim AJ, Ro H, Chang JH, Lee HH, Chung W, Lee C, Jung JY.
    PLoS One; 2017 Oct 15; 12(1):e0170874. PubMed ID: 28122064
    [Abstract] [Full Text] [Related]

  • 39. Inhibition of the renin-angiotensin-aldosterone system for cerebrorenal protection.
    Lambers Heerspink HJ.
    Contrib Nephrol; 2013 Oct 15; 179():7-14. PubMed ID: 23652444
    [Abstract] [Full Text] [Related]

  • 40. Intensity of hydration changes the role of renin-angiotensin-aldosterone system blockers in contrast-induced nephropathy risk after coronary catheterisation in patients with chronic kidney disease.
    Guo XS, Wu DX, Bei WJ, Li HL, Wang K, Zhou YL, Duan CY, Chen SQ, Lian D, Li LW, Liu Y, Tan N, Chen JY.
    J Renin Angiotensin Aldosterone Syst; 2017 Oct 15; 18(2):1470320317708894. PubMed ID: 28490226
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.